Risk of scar in the comparison of age-related macular degeneration treatments trials.

[1]  Glenn J Jaffe,et al.  Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. , 2013, Ophthalmology.

[2]  Sandra S Stinnett,et al.  Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. , 2012, Ophthalmology.

[3]  R. Tadayoni,et al.  CAUSES OF UNSUCCESSFUL RANIBIZUMAB TREATMENT IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION IN CLINICAL SETTINGS , 2012, Retina.

[4]  Ebenezer Daniel,et al.  Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. , 2012, Ophthalmology.

[5]  M. Moschos,et al.  LONG-TERM RESULTS OF INTRAVITREAL RANIBIZUMAB, INTRAVITREAL RANIBIZUMAB WITH PHOTODYNAMIC THERAPY, AND INTRAVITREAL TRIAMCINOLONE WITH PHOTODYNAMIC THERAPY FOR THE TREATMENT OF RETINAL ANGIOMATOUS PROLIFERATION , 2012, Retina.

[6]  Laura G. Qualls,et al.  Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries. , 2012, American journal of ophthalmology-glaucoma.

[7]  C. Toth,et al.  Reproducibility of Optical Coherence Tomography Image Grading During the Comparisons of Age-Related Macular Degeneration Treatments Trials (CATT) , 2012 .

[8]  R. Goldschmeding,et al.  A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy , 2012, British Journal of Ophthalmology.

[9]  R. Zawadzki,et al.  TEN-YEAR FOLLOW-UP OF EYES TREATED WITH STEREOTACTIC FRACTIONATED EXTERNAL BEAM RADIATION FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2011, Retina.

[10]  D. Roth,et al.  The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. , 2011, Ophthalmology.

[11]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[12]  P. Rosenfeld,et al.  Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. , 2011, Ophthalmology.

[13]  John C. Hwang,et al.  Development of subretinal fibrosis after anti-VEGF treatment in neovascular age-related macular degeneration. , 2011, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[14]  E. O'Neill,et al.  Antifibrotic activity of bevacizumab on human Tenon's fibroblasts in vitro. , 2010, Investigative ophthalmology & visual science.

[15]  Yusuke Nakamura,et al.  A genome-wide association study identifies four susceptibility loci for keloid in the Japanese population , 2010, Nature Genetics.

[16]  W. Spileers,et al.  Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. , 2009, Investigative ophthalmology & visual science.

[17]  R. Varma,et al.  Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. , 2009, Investigative ophthalmology & visual science.

[18]  G. Staurenghi,et al.  RETINAL ANGIOMATOUS PROLIFERATION: Natural History and Progression of Visual Loss , 2009, Retina.

[19]  P. Presti,et al.  Relationships between clinical measures of visual function and anatomic changes associated with bevacizumab treatment for choroidal neovascularization in age-related macular degeneration , 2009, Eye.

[20]  V. Bergdall,et al.  Regulation of scar formation by vascular endothelial growth factor , 2008, Laboratory Investigation.

[21]  J. Vander,et al.  Ranibizumab for Predominantly Classic Neovascular Age-related Macular Degeneration: Subgroup Analysis of First-year ANCHOR Results , 2008 .

[22]  Usha Chakravarthy,et al.  The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. , 2008, Ophthalmology.

[23]  Peter K Kaiser,et al.  Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. , 2007, Ophthalmology.

[24]  Gerald Liew,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2007, The New England journal of medicine.

[25]  J. Vander.  Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationBrown DM, for the ANCHOR Study Group (Methodist Hosp, Houston; et al) N Engl J Med 355:1432–1444, 2006§ , 2007 .

[26]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[27]  J. V. van Meurs,et al.  Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye. , 2006, Archives of ophthalmology.

[28]  P. Beaumont,et al.  Lesion morphology in age-related macular degeneration and its therapeutic significance. , 2006, Archives of ophthalmology.

[29]  Peter K. Kaiser,et al.  ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006 .

[30]  G. Saleh,et al.  Does lesion size determine the success rate of photodynamic therapy for age-related macular degeneration? , 2006, Eye.

[31]  D. Pauleikhoff,et al.  NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Natural History and Treatment Outcomes , 2005, Retina.

[32]  C. Kanellitsas,et al.  The Age-Related Macular Degeneration Radiotherapy Trial ( AMDRT ) : One Year Results from a Pilot Study , 2004 .

[33]  J. Winder,et al.  Identification of lesion components that influence visual function in age related macular degeneration , 2003, The British journal of ophthalmology.

[34]  M. Humayun,et al.  MORPHOMETRIC ANALYSIS OF THE MACULA IN EYES WITH DISCIFORM AGE-RELATED MACULAR DEGENERATION , 2002, Retina.

[35]  J W Berger,et al.  Age-related macular degeneration. , 2000, The New England journal of medicine.

[36]  P. Romano.  Association for Research in Vision and Ophthalmology. , 2000, Binocular vision & strabismus quarterly.

[37]  G. Soubrane,et al.  Natural History of Macular Subretinal Hemorrhage in Age-Related Macular Degeneration , 1999, Ophthalmologica.

[38]  M G Maguire,et al.  Occult choroidal neovascularization in age-related macular degeneration. A natural history study. , 1997, Archives of ophthalmology.

[39]  R. Avery,et al.  Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. , 1996, Retina.

[40]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[41]  W R Green,et al.  Age-related Macular Degeneration Histopathologic Studies: The 1992 Lorenz E. Zimmerman Lecture , 1993, Ophthalmology.

[42]  R P Murphy,et al.  Natural course of poorly defined choroidal neovascularization associated with macular degeneration. , 1988, Archives of ophthalmology.

[43]  A. Bird,et al.  Senile disciform macular degeneration in the second eye. , 1977, The British journal of ophthalmology.

[44]  H. Zauberman,et al.  The macular vessels in predisciform and disciform senile macular degeneration. , 1970, American journal of ophthalmology.

[45]  C. Walker.  Ophthalmology , 1859, Bristol medico-chirurgical journal.